PBR Nachrichten

 

Known as Telix Manufacturing Solutions North Melbourne (TMSNM), the site is described as the country's first purpose-built facility to combine radiochemistry laboratories, clinical manufacturing, patient dose administration, and The post Telix opens radiopharmaceutical facility in Australia for cancer treatment appeared first on Pharmaceutical Business review....

HBM7575/SKB575 is designed to target thymic stromal lymphopoietin (TSLP) as well as an undisclosed antigen. The long-acting antibody uses a dual mechanism of action. It works to block The post Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy appeared first on Pharmaceutical Business review....

The decision is based on results from the Phase III MAJESTY study, which indicated that Gazyva/Gazyvaro achieved a higher rate of complete remission at two years compared to The post FDA grants priority review to Roche's Gazyva/Gazyvaro for pMN appeared first on Pharmaceutical Business review....

IBI355 is an Fc-silent, third-generation anti-CD40L antibody that is expected to advance to Phase II trials for immunoglobulin G4 (IgG4)-related disease. Spero plans to launch a global Phase The post Innovent licenses IBI355 rights to Spero for up to $1.1bn appeared first on Pharmaceutical Business review....

The agreement grants Novartis access to Chai Discovery's latest AI models, including its Chai-3 model, to support antibody discovery efforts across a range of therapeutic targets. The partnership The post Novartis and Chai Discovery collaborate on antibody identification appeared first on Pharmaceutical Business review....

SBT-77-7101 is described as an autologous CAR-Treg cell therapy currently in Phase I clinical development to treat patients with poly-refractory rheumatoid arthritis (RA). These patients with RA have The post Cellares and Sonoma partner to automate cell therapy manufacturing appeared first on Pharmaceutical Business review....

The Ministry of Health of the Republic of Indonesia (BKPM) has issued a fractionation licence to Takeda, allowing the company to collect and process plasma as part of The post Takeda and Indonesia partner on plasma-derived therapies appeared first on Pharmaceutical Business review....

The new approvals for the anti-programmed death-1 (PD-1) therapies cover both neoadjuvant (pre-surgery) and adjuvant (post-surgery) treatment and apply to patients regardless of their eligibility for cisplatin. These The post FDA approves MSD's Keytruda combinations for MIBC appeared first on Pharmaceutical Business review....

Under the deal, Teva will hold exclusive rights to commercialise both intravenous and subcutaneous formulations of the biosimilar once it obtains regulatory approval. The arrangement covers markets, including The post Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar appeared first on Pharmaceutical Business review....

The company signed the agreement to test the investigational therapy with Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Human Genome The post Apertura and NIH institutes to test gene therapy for NPC1 appeared first on Pharmaceutical Business review....

AstraZeneca will obtain a licence to develop, manufacture and commercialise the phosphodiesterase 3/4 (PDE3/4) inhibitor, TQC3721, outside China. The agreement also covers certain future development programmes on an The post Sino and AstraZeneca sign licence agreement for TQC3721 appeared first on Pharmaceutical Business review....

Facilitated by Ramot, which manages technology transfer for Tel Aviv University, the agreement will combine computational and experimental tools for academic teams and scientific entrepreneurs seeking to advance The post Evogene and Tel Aviv University launch drug discovery initiative appeared first on Pharmaceutical Business review....

The FDA's Office of Orphan Products Development and Office of Pediatric Therapeutics granted this status to the therapy. CMT2S is a rare, inherited neurological condition that progressively causes The post FDA grants rare paediatric designation to Vanda's CMT2S therapy appeared first on Pharmaceutical Business review....

Under this collaboration, Biocytogen will offer access to up to five bispecific antibodies via its RenLite platform. Whitehawk Therapeutics will assess them in conjunction with its own ADC The post Biocytogen and Whitehawk partner to develop ADCs appeared first on Pharmaceutical Business review....

Approved unanimously by both companies' boards, the acquisition will see Vertex pay $85.00 per share in cash for all outstanding shares of Crinetics. It is expected to close The post Vertex signs agreement to acquire Crinetics for $10bn appeared first on Pharmaceutical Business review....

The decision is based on data from the pivotal Phase III EPCORE FL-1 trial, which assessed the efficacy and safety of the fixed-duration Tepkinly plus lenalidomide and rituximab The post EC approves AbbVie's Tepkinly combination for follicular lymphoma appeared first on Pharmaceutical Business review....

The deal includes an upfront payment of $1.1bn and up to $400m in potential milestone payments. It is expected to close in the second half of 2026, pending The post Novartis to acquire Myricx Bio in up to $1.5bn deal appeared first on Pharmaceutical Business review....

UniD Manufacturing's expertise includes advanced polymer systems used in complex delivery formats such as implants and vaginal rings. Besins Healthcare will acquire UniD's site in Seraing, Belgium. A The post Besins Healthcare boosts drug delivery portfolio with UniD deal appeared first on Pharmaceutical Business review....

The project will involve collaboration with global health organisation PATH and consulting firm Slalom. The initiative seeks to create a platform that uses AI to analyse a wide The post SK bioscience to lead Gates Foundation-funded ROTOR project appeared first on Pharmaceutical Business review....

With this decision, Itvisma becomes the only gene replacement therapy which is currently approved for this wider patient population within the EU. Itvisma works by providing a functional The post European Commission approves Novartis' Itvisma to treat SMA appeared first on Pharmaceutical Business review....